Management of Dengue with Hematuria
Hospitalize immediately and initiate close monitoring for progression to severe dengue, as hematuria represents a warning sign of plasma leakage and potential hemorrhagic complications requiring aggressive supportive care. 1
Initial Risk Stratification
Classify the patient into one of three categories upon presentation: dengue without warning signs, dengue with warning signs, or severe dengue. Hematuria places this patient automatically into at least the "dengue with warning signs" category, mandating hospital admission. 1, 2
Recognize that hematuria is a mucosal bleeding manifestation and a critical warning sign indicating increased risk for progression to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). 2
Obtain baseline laboratory studies immediately: complete blood count with hematocrit and platelet count, liver function tests, coagulation profile (PT/PTT, fibrinogen, D-dimer), renal function (creatinine, BUN), and urinalysis with urine protein-creatinine ratio (UPCR). 2, 3
Diagnostic Confirmation
For symptoms ≤7 days from onset, order dengue PCR/NAAT on serum as the preferred diagnostic test, since viral RNA remains detectable for 4-6 days after symptom onset. 4, 1
If symptoms are >7 days or PCR is unavailable, perform IgM capture ELISA as the primary diagnostic test. 4, 1
Document complete vaccination history to interpret serologic results accurately, as cross-reactivity with other flavivirus vaccines (yellow fever, Japanese encephalitis, Zika) can cause false-positive IgM results. 4
Monitoring Strategy During Hospitalization
Monitor complete blood count with hematocrit and platelet count every 6-12 hours during the critical phase (days 3-7 of illness) to detect rising hematocrit (>20% increase from baseline) indicating plasma leakage. 1, 2
Track vital signs every 2-4 hours: blood pressure, pulse pressure (critical threshold ≤20 mmHg), heart rate, capillary refill time, and urine output (target >0.5 mL/kg/hour in adults). 1, 2
Assess for progression to severe dengue: worsening abdominal pain, persistent vomiting, increasing lethargy or restlessness, cold clammy extremities, narrowing pulse pressure, or hypotension. 1, 2
Monitor urine output closely and repeat urinalysis daily to assess for worsening hematuria or development of proteinuria, which correlates with disease severity. 4, 3
Fluid Management Protocol
Initiate aggressive oral hydration with a target of 2,500-3,000 mL daily using oral rehydration solutions if the patient is hemodynamically stable and can tolerate oral intake. Avoid soft drinks due to high osmolality. 1, 2
If the patient develops signs of shock (hypotension, pulse pressure ≤20 mmHg, cold extremities), administer 20 mL/kg isotonic crystalloid bolus over 5-10 minutes and reassess immediately after completion. 1, 2
Repeat crystalloid boluses up to 40-60 mL/kg in the first hour if shock persists after the initial bolus, before escalating to colloid solutions or vasopressors. 1
Consider colloid solutions (albumin, dextran) for severe shock with pulse pressure <10 mmHg when crystalloids alone fail to restore perfusion. 1, 2
Management of Bleeding Complications
Avoid prophylactic platelet transfusion unless there is active significant bleeding or the patient requires invasive procedures with platelet count <20,000/mm³. 1
Transfuse packed red blood cells if hemoglobin drops below 10 g/dL with evidence of tissue hypoperfusion (ScvO2 <70%) or ongoing significant bleeding. 1
Monitor coagulation parameters closely and consider fresh frozen plasma if PT/PTT are significantly prolonged with active bleeding. 2
Symptomatic Management
Use acetaminophen at standard doses (650-1000 mg every 6 hours, maximum 4 g/day) as the only acceptable analgesic for fever and pain control. 1, 2
Never administer aspirin or NSAIDs as they worsen bleeding tendencies through platelet dysfunction and increase the risk of hemorrhagic complications. 1, 2
Critical Pitfalls to Avoid
Do not delay fluid resuscitation once signs of shock appear, as cardiovascular collapse may rapidly follow hypotension in dengue shock syndrome. 1
Avoid excessive fluid administration in patients without shock, as this leads to fluid overload, pulmonary edema, and respiratory complications during the recovery phase. 1, 5
Do not miss the critical phase (days 3-7 of illness), when plasma leakage can rapidly progress to shock even if the patient initially appears stable. 1
Stop aggressive fluid resuscitation once signs of fluid overload appear (rising respiratory rate, decreased oxygen saturation, pulmonary crackles) and switch to diuretics or inotropic support as needed. 1
Special Considerations
If the patient is pregnant, test simultaneously for both dengue and Zika virus by NAAT regardless of outbreak patterns, due to risks of maternal death, hemorrhage, preeclampsia, and vertical transmission. 4, 1
If the patient has comorbidities (diabetes, hypertension, heart disease, renal impairment, immunosuppression), maintain an even lower threshold for ICU admission as these conditions increase the risk of severe dengue by 2-fold or more. 5
In patients with pre-existing renal disease, use a more restrictive fluid approach with close monitoring for fluid overload, and consider early renal replacement therapy if oliguria develops despite adequate resuscitation. 5
Discharge Criteria
Discharge only when all of the following criteria are met: afebrile for ≥48 hours without antipyretics, resolution or significant improvement of symptoms (including resolution of hematuria), stable hemodynamic parameters for ≥24 hours without support, adequate oral intake, urine output >0.5 mL/kg/hour, and laboratory parameters (platelet count, hematocrit) returning toward normal ranges. 1, 2
Instruct the patient to return immediately if fever recurs, vomiting resumes, severe abdominal pain develops, bleeding worsens, or signs of shock appear (dizziness, cold extremities, decreased urine output). 1